Subject(s)
Antineoplastic Agents/economics , Neoplasms/drug therapy , Drug Costs , Humans , Survival AnalysisABSTRACT
Advanced melanoma has a poor prognosis and chemotherapy provides little benefit for most patients. This may be related to heterogeneity of chemosensitivity as well as frequent constitutive resistance to individual cytotoxic drugs. We have therefore examined the heterogeneity of chemosensitivity in metastatic cutaneous melanoma specimens using an ex vivo ATP-based chemosensitivity assay (ATP-TCA). Melanoma deposits (n=55) in skin or lymph node were tested using the ATP-TCA, performed in three separate laboratories. Analysis of the data collected (based on an arbitrary sensitivity index < 300) shows considerable heterogeneity of chemosensitivity. The most active single cytotoxic agents in the assay were identified as cisplatin, treosulfan, paclitaxel, vinblastine, gemcitabine and mitoxantrone. There was also a limited direct inhibition of melanoma cell growth by interferon-alpha2b, although this agent is known to have a number of indirect biological antitumor effects. Exposure of tumor cells to combinations of drugs at the concentrations tested as single agents showed the most active combinations to be treosulfan+gemcitabine, cisplatin+paclitaxel and vinblastine+paclitaxel. There was considerable heterogeneity of chemosensitivity: some tumors responded well to one agent or combination, while others showed no response to this and instead responded to one of the alternatives tested. Occasional highly resistant tumors showed no response to any of the single agents or combinations tested. The degree of heterogeneity observed suggests that the ATP-TCA could be used to select patients who might benefit from specific chemotherapeutic agents alone or in combination. This provides the rationale for future randomized controlled trials of ATP-TCA-directed chemotherapy versus physician's choice to determine whether assay-directed chemotherapy can improve patient response and survival.
Subject(s)
Melanoma/drug therapy , Skin Neoplasms/drug therapy , Adenosine Triphosphate/metabolism , Adult , Aged , Aged, 80 and over , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Drug Screening Assays, Antitumor , Female , Humans , Male , Middle AgedABSTRACT
PURPOSE: Fludarabine phosphate (F-AMP), a purine analog, requires daily intravenous administration. A pharmacokinetic study of an oral formulation (10 mg immediate-release tablet) was undertaken in patients with "low-grade" non-Hodgkin's lymphoma and B-cell chronic lymphocytic leukemia. PATIENTS AND METHODS: Oral F-AMP was incorporated into the "conventional" treatment schedule. Single oral trial doses of 50, 70, and 90 mg of F-AMP were given on the first day of three cycles of treatment; a comparative 50-mg intravenous trial dose was given on the first day of the fourth cycle. Intravenous F-AMP (25 mg/m2) was given on days 2 to 5 at 4-week intervals. Pharmacokinetic samples taken after each trial dose were analyzed for plasma 2-fluoro-arabinofuranosyladenine (2F-ara-A) concentration (its main metabolite); area under the curve 0 to 24 hours (AUC(0-24h)) and maximum concentration (Cmax) were calculated. Eighteen patients received all three oral trial doses, and bioavailability was determined in 15 patients who completed four courses of therapy. RESULTS: Oral administration of F-AMP resulted in a dose-dependent increase in Cmax and AUC(0-24h) of 2F-ara-A and achieved an AUC(0-24h) similar to intravenous administration, although at a lower Cm. The linear increase in mean AUC(0-24h) by factors of 1.36 +/- 0.22 (mean +/- SD) and 1.72 +/- 0.31 corresponded well with the increase in oral dose from 50 to 70 mg (factor of 1.4) and 90 mg (factor of 1.8), respectively. Bioavailability (approximately 55%, with low intraindividual variation) and time to Cmax were dose independent. CONCLUSION: Oral doses of F-AMP can achieve an AUC(0-24h) of 2F-ara-A similar to intravenous administration, with dose-independent bioavailability. The tablet will greatly enhance the use of F-AMP in a palliative setting.
Subject(s)
Antimetabolites, Antineoplastic/pharmacokinetics , Leukemia, Lymphocytic, Chronic, B-Cell/blood , Lymphoma, Non-Hodgkin/blood , Vidarabine Phosphate/analogs & derivatives , Administration, Oral , Adult , Aged , Antimetabolites, Antineoplastic/administration & dosage , Antimetabolites, Antineoplastic/adverse effects , Area Under Curve , Biological Availability , Cross-Over Studies , Drug Administration Schedule , Female , Humans , Leukemia, Lymphocytic, Chronic, B-Cell/drug therapy , Lymphoma, Non-Hodgkin/drug therapy , Male , Middle Aged , Prospective Studies , Vidarabine Phosphate/administration & dosage , Vidarabine Phosphate/adverse effects , Vidarabine Phosphate/pharmacokineticsABSTRACT
Many advances in the management of melanoma have occurred in the last few years. These make this an exciting time for clinicians and allows them to offer glimmers of hope for patients with this disease. This article looks at the therapeutic aspects of the treatment of cutaneous melanoma.
Subject(s)
Melanoma/therapy , Skin Neoplasms/therapy , Humans , Medical Oncology/trends , Melanoma/pathology , Melanoma/secondary , Skin Neoplasms/pathology , Skin Neoplasms/secondaryABSTRACT
We report a Phase I/II clinical trial of poly-(styrene-co-maleyl-half-n-butylate)-neocarzinostatin (SMANCS) for intra-arterial treatment of hepatoma. Early patients received 4 or 8 mg SMANCS dissolved in Lipiodol; later patients were treated according to tumour size and degree of filling achieved. SMANCS/Lipiodol drained rapidly from normal liver but was retained within tumour interstitium. Tumour nodules filled with SMANCS/Lipiodol usually stabilised and often regressed. No UICC criteria-defined responses were achieved, partly due to difficulties of filling several lesions simultaneously. Signs of therapeutic activity suggest a more extensive clinical study is warranted.
Subject(s)
Antineoplastic Agents/therapeutic use , Carcinoma, Hepatocellular/drug therapy , Liver Neoplasms/drug therapy , Maleic Anhydrides/therapeutic use , Polystyrenes/therapeutic use , Zinostatin/analogs & derivatives , Abdominal Pain/chemically induced , Adult , Aged , Antineoplastic Agents/administration & dosage , Antineoplastic Agents/adverse effects , Carcinoma, Hepatocellular/diagnostic imaging , Drug Evaluation , Drug Hypersensitivity/etiology , Female , Fever/chemically induced , Humans , Hypotension/chemically induced , Injections, Intra-Arterial , Liver/diagnostic imaging , Liver/pathology , Liver Neoplasms/diagnostic imaging , Male , Maleic Anhydrides/administration & dosage , Maleic Anhydrides/adverse effects , Middle Aged , Polystyrenes/administration & dosage , Polystyrenes/adverse effects , Radiography , Syncope/chemically induced , Treatment Outcome , Zinostatin/administration & dosage , Zinostatin/adverse effects , Zinostatin/therapeutic use , alpha-Fetoproteins/analysis , alpha-Fetoproteins/metabolismABSTRACT
The case report of a patient known to have metastatic renal cancer and right main bronchus obstruction is presented. During an episode of haemoptysis, the patient expectorated a large fragment of tissue, which proved to be metastatic renal cell cancer. This event produced a right-sided hydropneumothorax with partial re-expansion of the previously collapsed right lung. A chest tube was inserted producing a full re-expansion, following which pleurodesis with tetracycline was performed. To our knowledge, this is the first ever description of spontaneous clearance of a malignant bronchial obstruction.
Subject(s)
Carcinoma, Renal Cell/secondary , Hemoptysis/etiology , Kidney Neoplasms/pathology , Pneumothorax/etiology , Bronchial Diseases/etiology , Carcinoma, Renal Cell/diagnostic imaging , Cough , Humans , Lung Neoplasms/diagnostic imaging , Lung Neoplasms/secondary , Lymphatic Metastasis , Male , Middle Aged , Radiography, ThoracicABSTRACT
PLD is regulated by the small GTP binding proteins Rho and Arf, though predominantly by the latter. The PA product of PLD activation is an activator of Rho-regulated actin stress fibre formation and in invasive cells of MMP-9 synthesis and activation. Together this may explain the increased invasion of cells in response to PA.
Subject(s)
GTP-Binding Proteins/metabolism , Phospholipase D/metabolism , ADP-Ribosylation Factors , Actins/metabolism , Blotting, Western , Cell Membrane/enzymology , Cell Movement/physiology , Edetic Acid/pharmacology , Enzyme Activation , GTP-Binding Proteins/pharmacology , Guanosine 5'-O-(3-Thiotriphosphate)/metabolism , HL-60 Cells , Humans , Lipids/analysis , Metalloendopeptidases/metabolism , Phosphatidic Acids/metabolism , Phosphatidic Acids/pharmacology , rhoA GTP-Binding ProteinABSTRACT
Regional chemotherapy, from a theoretical and pharmacological stand point, would seem to offer significant advantage over systemic therapy for the treatment of hepatic metastatic colorectal cancer patients. Clinical experience has shown us that the technique itself is fraught with practical problems, but over the years, specialist centres have learned to overcome many of these, making the technique safer and minimising the possibility of complications and toxicity. As a consequence, there is no doubt that high response rates can be achieved with HAI fluoropyrimidines. However, randomised data have only been obtained from small numbers of patients in suboptimally designed trials and, to date, true patient benefit in terms of either survival or quality of life has not been adequately demonstrated. In parallel with the U.S. Intergroup study, the U.K.-based MRC phase III clinical trial of regional versus systemic 5-FU/FA warrants urgent support and we would welcome collaboration with interested European and American centres. The outcome of this trial will fully define the role of HAI chemotherapy in the management of unresectable hepatic metastatic colorectal cancer, in the context of modern, modulated 5-FU.
Subject(s)
Antineoplastic Agents/administration & dosage , Colorectal Neoplasms/pathology , Liver Neoplasms/drug therapy , Liver Neoplasms/secondary , Hepatic Artery , Humans , Infusions, Intra-Arterial , Randomized Controlled Trials as TopicSubject(s)
Breast Neoplasms/metabolism , Breast Neoplasms/secondary , Phosphatidic Acids/metabolism , Female , Guanosine 5'-O-(3-Thiotriphosphate)/pharmacology , Humans , Intracellular Fluid/metabolism , Neoplasm Invasiveness , Phospholipase D/metabolism , Tetradecanoylphorbol Acetate/pharmacology , Tumor Cells, CulturedABSTRACT
Alpha-foetoprotein (AFP) is widely used in the diagnosis, therapeutic monitoring and follow-up of patients with germ cell tumours. On occasion, the interpretation of a raised serum AFP measurement in a patient is confounded by the fact that AFP also increases in a variety of liver and gastrointestinal diseases. AFP exists as a number of isoforms, which can be separated by their differential binding to plant lectins. Thus, AFP-concanavalin A (ConA) binding affords a means of distinguishing between a raised AFP of teratoma or liver aetiology and has recently been reported to possess sensitivity and specificity approaching 100%. We present a patient in whom column chromatographic ConA binding was used as a basis for clinical management decisions for treatment for relapsed germ cell testicular tumour. The presumption of high test specificity led to a delay in the diagnosis of cancer recurrence, from which the patient ultimately died. We conclude that the clinical utility of lectin binding assays currently remains uncertain and further evaluation is warranted.
Subject(s)
Biomarkers, Tumor/blood , Teratoma/blood , Testicular Neoplasms/blood , alpha-Fetoproteins/analysis , Adult , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Chromatography, Affinity , Combined Modality Therapy , Concanavalin A , Humans , Male , Orchiectomy , Radiotherapy Dosage , Sensitivity and Specificity , Teratoma/diagnosis , Teratoma/therapy , Testicular Neoplasms/diagnosis , Testicular Neoplasms/therapyABSTRACT
A patient presenting with congestive cardiac failure and anaemia underwent investigation which led to the diagnosis of Whipple's disease, associated with dilated cardiomyopathy. Conventional antibiotic therapy for Whipple's disease resulted in resolution of the traditional features of Whipple's disease and a marked improvement in the patient's heart failure.
Subject(s)
Heart Failure/etiology , Whipple Disease/complications , Aged , Anemia/etiology , Echocardiography , Heart Failure/drug therapy , Humans , Intestine, Small/pathology , Male , Tetracycline/therapeutic use , Whipple Disease/drug therapy , Whipple Disease/pathologyABSTRACT
A method is reported for the measurement of quercetin in human plasma using reversed-phase high-performance liquid chromatography (HPLC). Quercetin and kaempferol (as internal standard) were spiked into plasma samples and extracted using C18 Sep-Pak Light cartridges (efficiency > 85%). Flavonoids were eluted with aqueous acetone (50% v/v, pH 3.5), dried down and redissolved in aqueous acetone (45% v/v, pH 3.5). The increased osmolarity promoted a phase separation and the water-saturated acetone layer, containing the flavonoids, was analysed by HPLC with aqueous acetone mobile phase (45% v/v acetone in 250 mM sodium dihydrogen sulphate. The mixture was adjusted to pH 3.5 with phosphoric acid and used at a flow-rate of 1.0 ml/min) and mu Bondapak C18 column (150 x 3.9 mm I.D., 10 microns particle size). The detection limit (A375 nm) for quercetin in plasma was 0.1 microgram/ml (300 nM). The method also detects metabolites of quercetin, although these are not yet identified.
Subject(s)
Chromatography, High Pressure Liquid/methods , Quercetin/blood , Humans , Reference Standards , Reproducibility of Results , Spectrometry, FluorescenceSubject(s)
Abortion, Induced , Abortion, Legal , Female , Humans , Pregnancy , Public Policy , Romania , United StatesABSTRACT
In this review, the rationale of regional chemotherapy for treatment of hepatic metastases in advanced colorectal carcinoma is discussed. Pharmacokinetic principles and early clinical experience of hepatic arterial drug administration are summarised. The regional advantage of fluoropyrimidine compounds in this setting is well established, and recent evidence suggests that 5-fluorouracil (5-FU) is more efficacious than the analogue 5-fluoro-2'-deoxyuridine (FUDR). However, while significantly higher clinical response rates can be achieved with hepatic arterial infusion (HAI) chemotherapy compared with conventional intravenous drug administration, patient survival benefit is not significantly different. Several novel approaches to overcome the limitations of HAI therapy are currently being explored. These include concomitant use of biodegradable microspheres, which both slow tumour blood flow and enhance tumour drug uptake, and use of vasoactive agents to redistribute arterial blood flow towards tumours. In addition, novel chemotherapeutic agents which exploit unique biological characteristics of hepatic tumours are entering clinical trial.
Subject(s)
Colorectal Neoplasms , Hepatic Artery , Liver Neoplasms/drug therapy , Liver Neoplasms/secondary , Floxuridine/administration & dosage , Fluorouracil/administration & dosage , Humans , Infusions, Intra-Arterial , Maleic Anhydrides/administration & dosage , Mitomycin/administration & dosage , Polystyrenes/administration & dosage , Zinostatin/administration & dosage , Zinostatin/analogs & derivativesABSTRACT
A series of 105 patients with operable breast cancer previously entered in the WMOA adjuvant therapy trials were reviewed in order to assess methods of treatment on relapse and subsequent patterns of relapse and survival, related to previous adjuvant therapy. Tamoxifen was the predominant medical therapy offered on relapse. Unexpectedly, analysis of the relapse and survival data for these hormone-treated patients suggested that prior adjuvant therapy negatively influenced response to tamoxifen, with overall survival of treated and control patients being identical. Although not statistically significant, possible explanations of this trend have been explored.